BG
NVLN

BlackRock Group’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

BlackRock Group’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$84K Buy
+9,930
New +$88K ﹤0.01% 2859

Other funds holding NVLN

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kingstown Capital Management New York $30.4M AUM 3.71% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock Group's NVLN Position: Q4 2016 in Review

BlackRock Group opened a new position in Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2016: 9,930 shares worth $84K. The stake represents ﹤0.01% of the portfolio and ranks #2859 among its holdings.

66 funds tracked by Wall St. Rank hold NVLN as of Q4 2016.

  • BlackRock Group held 9,930 shares of Novelion Therapeutics Inc. Common Shares worth $84K as of Q4 2016.
  • Novelion Therapeutics Inc. Common Shares was a new BlackRock Group position in Q4 2016.
  • Novelion Therapeutics Inc. Common Shares made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2859 holding.
  • 66 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.